Skip to content

Study · In vitro (cells) · 2019

2 results

Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.

Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F, Korbonits M

Endocrine-related cancer1 Dec 2019Cited by 53 (Europe PMC)

PMID31645017 (opens in a new tab)DOI10.1530/erc-19-0327 (opens in a new tab)PepBankPUB-31645017
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In cultured PitNET-derived fibroblasts, pasireotide decreased IL-6 release by 80% (P<0.001).

    In plain wordsIn lab tests, pasireotide decreased IL-6 release from pituitary tumour fibroblasts compared with before treatment.

    Peptide
    Pasireotide
    Outcome
    DecreaseIL-6 release
    Study

    humann: not reported in source

    PitNET-derived tumour-associated fibroblasts
    Outcome group
    Inflammation markers · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SST1 is the predominant somatostatin receptor in TAFs, and pasireotide decreased TAF-derived IL-6 by 80% (P < 0.001) and CCL2 by 35% (P = 0.038).
    2 context sentences
    Summary · context
    TAFs were isolated and cultured from 16 PitNETs (11 clinically non-functioning tumours and 5 somatotropinomas).
    Summary · context
    The fibroblast secretome was assessed with a 42-plex cytokine array before and after multiligand somatostatin receptor agonist pasireotide treatment.
  2. 02LabIn vitro (cells)Mechanism

    In cultured PitNET-derived fibroblasts, pasireotide decreased CCL2 release by 35% (P=0.038).

    In plain wordsIn lab tests, pasireotide decreased CCL2 release from pituitary tumour fibroblasts compared with before treatment.

    Peptide
    Pasireotide
    Outcome
    DecreaseCCL2 release
    Study

    humann: not reported in source

    PitNET-derived tumour-associated fibroblasts
    Outcome group
    Inflammation markers · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SST1 is the predominant somatostatin receptor in TAFs, and pasireotide decreased TAF-derived IL-6 by 80% (P < 0.001) and CCL2 by 35% (P = 0.038).
    2 context sentences
    Summary · context
    TAFs were isolated and cultured from 16 PitNETs (11 clinically non-functioning tumours and 5 somatotropinomas).
    Summary · context
    The fibroblast secretome was assessed with a 42-plex cytokine array before and after multiligand somatostatin receptor agonist pasireotide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.